--- title: "Telesis Bio, Inc. (TBIO.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/TBIO.US.md" symbol: "TBIO.US" name: "Telesis Bio, Inc." industry: "Life Sciences Tools and Services" datetime: "2026-05-21T10:14:20.696Z" locales: - [en](https://longbridge.com/en/quote/TBIO.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/TBIO.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/TBIO.US.md) --- # Telesis Bio, Inc. (TBIO.US) ## Company Overview Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It has license agreement with Regeneron Pharmaceuticals, Inc. | Item | Detail | |------|--------| | Industry | Life Sciences Tools and Services | | Exchange | US Market | | Website | [elesisbio.com](https://elesisbio.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:19.000Z **Overall: D (0.68)** **Industry**: Life Sciences Tools and Services | Metric | Value | |--------|-------| | Industry Ranking | 56 / 59 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -32.54% | | | Net Profit YoY | -23.23% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1801.85 | | | Revenue | 17034000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 1003.77% | A | | Profit Margin | -267.41% | E | | Gross Margin | 64.43% | A | | Revenue YoY | -32.54% | E | | Net Profit YoY | -23.23% | D | | Total Assets YoY | -76.45% | E | | Net Assets YoY | -91.67% | E | | Cash Flow Margin | 47.72% | C | | OCF YoY | -32.54% | E | | Turnover | 0.26 | D | | Gearing Ratio | 84.34% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Telesis Bio, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-32.54%", "rating": "" }, { "name": "Net Profit YoY", "value": "-23.23%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "1801.85", "rating": "" }, { "name": "Revenue", "value": "17034000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "1003.77%", "rating": "A" }, { "name": "Profit Margin", "value": "-267.41%", "rating": "E" }, { "name": "Gross Margin", "value": "64.43%", "rating": "A" }, { "name": "Revenue YoY", "value": "-32.54%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-23.23%", "rating": "D" }, { "name": "Total Assets YoY", "value": "-76.45%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-91.67%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "47.72%", "rating": "C" }, { "name": "OCF YoY", "value": "-32.54%", "rating": "E" }, { "name": "Turnover", "value": "0.26", "rating": "D" }, { "name": "Gearing Ratio", "value": "84.34%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 0.00 | 22/59 | - | - | - | | PB | 0.00 | 57/59 | - | - | - | | PS (TTM) | 0.01 | 1/59 | 0.01 | 0.01 | 0.00 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A | | 02 | Agilent Tech (A.US) | A | C | B | C | C | B | | 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B | | 04 | Illumina (ILMN.US) | A | C | B | D | C | B | | 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TBIO.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TBIO.US/norm.md) - [Related News](https://longbridge.com/en/quote/TBIO.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TBIO.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**